PROGRAM
All Times are ET
Program is subject to change
Saturday, February 7, 2026
| 6:50 am | Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, Harry W. Flynn, Jr., and Thomas A. Albini |
| Session I: AMD: Imaging and Disease Progression Moderators: Giovanni Gregori, Philip J. Rosenfeld, and Zohar Yehoshua Panelists: Christine A. Curcio, Emily Y. Chew, Aaron Y. Lee, Pearse Keane, Viet-Hoan Le, Omar El-Mulki, Ruikang (Ricky) Wang, Yunchan Hwang, Alessandro Berni, and Robyn Guymer |
|
| 7:00 | New Imaging Analytics and Insights for Macular Xanthophyll Carotenoids in Aging and AMD: ALSTAR 2 Christine A. Curcio |
| 7:10 | CART Analyses of OCT Classification of AMD Emily Y. Chew |
| 7:20 | AMD Continuous Severity Prediction from Retinal OCT Using Temporal Pairwise Supervision Aaron Y. Lee |
| 7:30 | Building a Database of Patients with Early and Intermediate AMD and Long-Term Follow-Up Pearse Keane |
| 7:40 | Characterizing Drusen with Hyporeflective Cores in OCT Images Viet-Hoan Le |
| 7:50 | Do Calcified Drusen and Drusen with Hyporeflective Cores Predict the Onset of Large Choroidal Hypertransmission Defects in Intermediate AMD? Omar El-Mulki |
| 8:00 | OCTA Imaging of Choriocapillaris in AMD: Practical Considerations Ruikang (Ricky) Wang |
| 8:10 | Choriocapillaris Hemodynamic Impairment in Hypertransmission Defects: VISTA OCTA Yunchan Hwang |
| 8:20 | Novel Clinical Trial Designs for Intermediate AMD Alessandro Berni |
| 8:30 | Nanosecond Laser Treatment Allows the Progressive Loss of the OCT Outer Retinal Bands in iAMD Eyes Without Coexistent RPD Robyn Guymer |
| Session II: Photoreceptors and AI in AMD Moderators: Omer Trivizki, Jaclyn Kovach, and Philip J. Rosenfeld Panelists: SrinVas R. Sadda, Giovanni Staurenghi, Karl Csaky, Amitha Domalpally, Justis P. Ehlers, Ursula Schmidt-Erfurth, Barbara Blodi, David Eichenbaum, Diana V. Do, and Marc Steffen Schmitz-Valckenberg |
|
| 8:40 | Validation of Photoreceptor Metrics for AMD Using AOSLO SriniVas R. Sadda |
| 8:50 | Elipsoid Zone Measurement: Pros and Cons Giovanni Staurenghi |
| 9:00 | Further Assessments of Cone Structure – Function in Non-Foveal Geographic Atrophy Karl Csaky |
| 9:10 | Methods for Assessing Photoreceptor Loss in GA Amitha Domalpally |
| 9:20 | The Impact of Pseudodrusen on Ellipsoid Zone Integrity Measures in Dry AMD Justis P. Ehlers |
| 9:30 | Accuracy and Reliability of AI-based Assessment of Ellipsoid Zone (EZ) Loss and Thinning in Geographic Atrophy (GA) Ursula Schmidt-Erfurth |
| 9:40 | Use of an AI Algorithm by Retina Specialists in Prescreening GA Patients for Possible Trial Enrollment Barbara Blodi |
| 9:50 | A Proof-of-Concept (PoC) Study for Candidate Identification in Geographic Atrophy: Potential for Enrollment Efficiency and Enrichment using an AI-driven Workflow David Eichenbaum |
| 10:00 | AI in GA: Learnings from the Pegcetacoplan Clinical Program Diana V. Do |
| 10:10 | AI-Powered Prediction of Retinal Function by OCT Imaging in Geographic Atrophy Marc Steffen Schmitz-Valckenberg |
Session III: Geographic Atrophy in AMD Moderators: Philip J. Rosenfeld, Omer Trivizki, and Jesse Sengillo Panelists: Seung-Young Yu, Gemmy Cheung Chui Ming, Giselle Herrera, Liangbo Linus Shen, Sara Beqiri, Roy Schwartz, Glenn J. Jaffe, and David R. Lally |
| 10:20 | Imaging-Based Prediction of Geographic Atrophy Progression Using En Face OCT and FAF Seung-Young Yu |
| 10:30 | Incident Atrophy and Macular Neovascularization in Fellow Eyes of nAMD over 3 Years Gemmy Cheung Chui Ming |
| 10:40 | Measuring Enlargement Rates of Large Choroidal Hypertransmission Defects over a Wide Range of Lesion Sizes in AMD Gissel Herrera |
| 10:50 | Concordance in Bilateral Geographic Atrophy: Morphology and Growth Rate Endpoints in AREDS Liangbo Linus Shen |
| 11:00 | The Symmetry of Atrophy Enlargement in AMD Eyes with Bilateral Atrophy Sara Beqiri |
| 11:10 | The Structure–Function Paradox in Geographic Atrophy: Limitations of BCVA as a Measure of Progression Roy Schwartz |
| 11:20 | Correlation of Foveal Invasion with Visual Function at Baseline in the Regeneron SIENNA Geographic Atrophy C5 Inhibitor Trial Glenn J. Jaffe |
| 11:30 | Controversy on AREDS Supplements and Geographic Atrophy David R. Lally |
| Session IV: Emerging Therapies for Non-Exudative AMD Moderators: Nicolas A. Yannuzzi, Philip J. Rosenfeld, and Omer Trivizki Panelists: Omer Trivizki, Mario Saravia, David N. Zacks, Anne Fung, Jayakrishna Ambati, Roger A. Goldberg, and Frank G. Holz |
|
| 11:40 | Ophthalmic Artery Stenosis in AMD, Rethinking the Role of Ocular Perfusion in AMD Omer Trivizki |
| 11:50 | A Feasibility Study of Balloon Angioplasty for the Treatment of Ophthalmic Artery Stenoses in Patients with Geographic Atrophy Mario Saravia |
| 11:55 | Fas Inhibition with Xelafaslatide: A Novel Approach for the Treatment of Geographic Atrophy David N. Zacks |
| 12:00 pm | One-time Intravitreal VOY-101 for Geographic Atrophy: Ph1 Update a Novel, Complement-Regulating Gene Therapy for Non-Neovascular AMD Anne Fung |
| 12:05 | Inflammasome Inhibition with Kamuvudine K8: A Phase II Clinical Trial in Bilateral Geographic Atrophy Jayakrishna Ambati |
| 12:15 | Once-daily Zervimesine as a Treatment for Geographic Atrophy: Results of the Phase 2 MAGNIFY Study Roger A. Goldberg |
| 12:25 | Vision Restoration with the PRIMA System in Geographic Atrophy Due to AMD Frank G. Holz |
| Session V: FDA-Approved Therapies for the Treatment of Non-Exudative AMD Moderators: Thomas A. Albini, Maura Di Nicola, and Philip J. Rosenfeld Panelists: Eleonora Lad, Nathan C. Steinle, Lawrence Singerman, Mathew MacCumber, Hasenin Al-khersan, Mengxi Shen, and Philip J. Rosenfeld |
|
| 12:35 | LIGHTSITE IIIB: An Open-Label, Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation in Subjects with Dry Age-Related Macular Degeneration Eleonora Lad |
| 12:45 | Factors Affecting GA Progression and Vision Loss in OAKS and DERBY Trials Nathan C. Steinle |
| 12:55 | 24-Month Results from the GALE Open- Label Extension Study: 48 Months of Continuous Pegcetacoplan Lawrence Singerman |
| 1:05 | Real-World Visual Acuity and Safety Outcomes from Using Complement Inhibitors for GA in AMD Mathew MacCumber |
| 1:15 | AI-Enabled Real-World Insights in GA: Challenges & Opportunities Hasenin Al-khersan |
| 1:25 | Real-World Efficacy of Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy Over 2 Years Mengxi Shen |
| 1:35 | Changes in Retinal and Optic Nerve Thickness Measurements Associated with Pegcetacoplan Therapy Philip J. Rosenfeld |
| Session VI: Imaging, Microperimetry, and Emerging Therapies for Exudative AMD Moderators: Lawrence Singerman, Luis J. Haddock, and Philip J. Rosenfeld Panelists: Giuseppe Querques, David Sarraf, Usha Chakravarthy, Monika Fleckenstein, Mark R. Barakat, Charles C. Wykoff, Allen C. Ho, Tong (Linda) Li, Arshad M. Khanani, and Rishi P. Singh |
|
| 1:45 | Fibrogliosis in Age-Related Macular Degeneration: A New Mechanistic Perspective Giuseppe Querques |
| 1:55 | Type 4 MNV: A New Addition to the OCT Classification of Neovascular AMD David Sarraf |
| 2:05 | Can iRORA and cRORA Definitions be Applied to Detect Macular Atrophy in Treated nAMD: Findings from the 5T BIG Study Usha Chakravarthy |
| 2:15 | Retinal Sensitivity Associated with Type-1 Macular Neovascularization Monika Fleckenstein |
| 2:25 | Randomized Phase 1b Trial of Faricimab vs OLN324, a Novel Bispecific Inhibitor of VEGF and Ang2: First-time results of the JADE trial in wet AMD and DME Charles C. Wykoff |
| 2:30 | OPTIC Trial: Long-Term Outcomes with Ixo-vec in nAMD Mark R. Barakat |
| 2:40 | Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular AMD: 2-year Efficacy and Safety Results from the Phase 2 LUNA Study Charles C. Wykoff |
| 2:50 | Subretinal Delivery of Investigational Surabgene Lomparvovec (Sura-vec; ABBV-RGX-314*) for Neovascular AMD: A Phase II Pharmacodynamic Study: 1-year Results Allen C. Ho |
| 3:00 | Subretinal LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD): Results of a Randomized, Active-Controlled Phase 2 Trial Tong (Linda) Li |
| 3:10 | Long-Term Follow-Up from the PRISM Study: 4D-150 for the Treatment of Neovascular AMD Arshad M. Khanani |
| 3:20 | Retinal Fluid Dynamics and Treatment Durability in nAMD: Insights from the DAVIO 2 Trial Rishi P. Singh |
| Session VII: Clinical Therapies for Exudative AMD, and Macular Edema due to Diabetic Retinopathy, Retinal Vascular Diseases, and Inflammation Moderators: Thomas A. Albini, Basil Williams, and Nicolas A. Yannuzzi Panelists: Anat Loewenstein, Mark R. Barakat, Carl Danzig, Veeral S. Sheth, Gemmy Cheung Chui Ming, Dante Pieramici, Peter A. Campochiaro, David M. Brown, Varun Chaudhary, John A. Wells, and Sumit Sharma |
|
| 3:30 | Longitudinal Validation and Real-World Management with Home OCT in Neovascular AMD Anat Loewenstein |
| 3:40 | Machine Learning based Volumetric Analysis of nAMD Biomarkers in Tenaya/Lucerne Mark R. Barakat |
| 3:50 | Four-Year Outcomes of Faricimab in nAMD: Safety and Efficacy Results From the AVONELLE-X Long-Term Extension Trial Carl Danzig |
| 4:00 | Global Real-World Data With Faricimab in nAMD and DME: The VOYAGER Study Veeral S. Sheth |
| 4:10 | Faricimab for Polypoidal Choroidal Vasculopathy: 1-Year Results from the Phase 3b/4 SALWEEN Trial Gemmy Cheung Chui Ming |
| 4:20 | Pagoda Trial Results Through Year 4: Port Delivery Platform with Ranibizumab for the Treatment of DME Dante Pieramici |
| 4:30 | Suppression of VEGF-A is Sufficient to Effectively Treat 95% of DME Patients Peter A. Campochiaro |
| 4:40 | Safety and Efficacy of Aflibercept 8 mg in Patients With nAMD or DME: Primary Results from the Phase 3b ELARA Trial David M. Brown |
| 4:50 | Aflibercept 8 mg in Macular Edema Following Retinal Vein Occlusion: Week 64 Results from the QUASAR Trial Varun Chaudhary |
| 5:00 | Safety Profile of Aflibercept 8 mg: A Pooled Analysis of the CANDELA, PULSAR, PHOTON, and QUASAR Trials John A. Wells |
| 5:10 | Bispecific Trap-antibody Inhibiting Interleukin-6 and Vascular Endothelial Growth Factor (KSI-101): Phase 1b APEX Study in Patients with Macular Edema Secondary to Inflammation (MESI) Sumit Sharma |
| Session VIII: Diabetic Retinopathy and Macular Telangiectasia Type 2 Moderators: Philip J. Rosenfeld, Justin H. Townsend, and William E. Smiddy Panelists: Sandy Wenting Zhou, Toshinori Murata, Jennifer K. Sun, Michael S. Ip, Jennifer I. Lim, Carl D. Regillo, Michael A. Singer, Veeral S. Sheth, Dilsher Dhoot, Baruch Kuppermann, Martin Friedlander, and W. Lloyd Clark |
|
| 5:15 | AI-Assisted Vascular Biomarker Evaluation in Diabetic Retinopathy On Ultrawide Field Swept-Source Optical Coherence Tomography Angiography - DRIVE Study Sandy Wenting Zhou |
| 5:25 | OCTA-Based Analysis of Leakage and Microaneurysms Using Enhanced AI-Inferred Fluorescein Angiography Toshinori Murata |
| 5:35 | Association of Retinal Nonperfusion with Vision Threatening Outcomes in Protocol AA Jennifer K. Sun |
| 5:45 | Structural OCT Biomarker Responses to Aflibercept, Ranibizumab, and Bevacizumab over 5 years: A Post Hoc Analysis of the DRCR Protocol T Michael S. Ip |
| 5:55 | Automated Quantification of the OCT Biomarker Retinal Fluid in Diabetic Macular Edema Treated with Faricimab Jennifer I. Lim |
| 6:05 | Danegaptide: A Novel, First-in-Class Oral Therapy for Patients with NPDR - Preclinical and Phase 1b Study Results Carl D. Regillo |
| 6:10 | Subcutaneous Migaldendranib (MGB) for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration: 40-Week Study Results from a Phase 2 Clinical Trial Michael A. Singer |
| 6:20 | PER-001: A Long-Acting Intravitreal Endothelin Antagonist for Structural and Functional Improvement in Diabetic Retinopathy Veeral S. Sheth |
| 6:30 | Suprachoroidal Delivery of Surabgene Lomparvovec (Sura-vec, ABBV-RGX-314): 2-Year Results in Non-Proliferative Diabetic Retinopathy Dilsher Dhoot |
| 6:40 | Efficacy and Safety Outcomes with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema from the DIAMOND Stage 1 Phase 2/3 Trial Baruch Kuppermann |
| 6:50 | What's New with MacTel 2? Martin Friedlander |
| 7:00 | Timing of Ocular Adverse Events in Pooled Analysis of Two Phase 3 Trials of Revakinagene Taroretcel-Iwey (NT-501) in MacTel Type 2 W. Lloyd Clark |
| Session IX: Inherited Retinal Degenerations Moderators: Byron L. Lam, Sander R. Dubovy, and Ninel Z. Gregori Panelists: Robert Bhisitkul, Peter K. Kaiser, Kenneth C. Fan, Byron L. Lam, Quan D. Nguyen, Nadia K. Waheed, and Fenghua Wang |
|
| 7:10 | Phase 1 WALLABY/PLATYPUS Studies of Intravitreal VP- 001 in PRPF31 Mutation-Associated Retinal Pigmentosa Robert Bhisitkul |
| 7:15 | LUCE: A First-in-Human Phase I/II Trial of Dual AAV8.MYO7A Gene Therapy in Subjects with Usher Syndrome Type1B Retinitis Pigmentosa Peter K. Kaiser |
| 7:25 | The TEASE Program: Evaluating Gildeuretinol in Early to Advanced Stages of Stargardt Disease Kenneth C. Fan |
| 7:35 | Safety and Efficacy of MCO-010 Phase 2 Optogenetic Therapy in Patients with Stargardt Disease Byron L. Lam |
| 7:45 | Topline Results of the Phase 3 DRAGON Study of Tinlarebant for Stargardt Disease Quan D. Nguyen |
| 7:55 | Clinical Trial and Imaging Results of a Phase 2 Study on RPGR Gene Therapy in X-Linked Retinitis Pigmentosa Nadia K. Waheed |
| 8:05 | Subretinal LX101 Gene Therapy for Biallelic RPE65 Mutation-Associated Inherited Retinal Dystrophy (IRD) Fenghua Wang |
| 8:15 | Post-Program Test and Closing Remarks |
| 8:20 | Meeting Adjourns |